drugset / Trial / NCT03676101
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Phase 1
Completed
90 enrolled
Shanghai Bovax Biotechnology Co., Ltd.
Chongqing Bovax Biopharmaceutical Co., Ltd. · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
To evaluate the safety and immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years.
Timeline
- Start
- 2018-10-10
- Primary completion
- 2019-08-20
- Completion
- 2020-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 9-valent HPV Recombinant Vaccine | Vaccine | — | — |